目的:评价Trousseau综合征相关脑梗死患者再灌注治疗的疗效及预后意义。
方法:描述性研究。研究的地点和持续时间:神经内科,厦门大学附属中山医院,医学院,厦门大学,厦门,中国,厦门医学院第二附属医院,厦门,中国,2017年1月至2023年12月。
方法:在两家医院接受治疗的Trousseau相关性脑梗死患者被纳入研究。临床结果,包括早期神经退化,颅内出血,住院死亡率,90天改良Rankin量表(mRS)评分,90天死亡率,初始和出院美国国立卫生研究院卒中量表(NIHSS)评分,和ΔNIHSS(初始和出院NIHSS评分之间的差异),在再灌注治疗组(n=9)和常规治疗组(n=23)之间进行比较。
结果:接受再灌注治疗的患者在出院时表现出显著的神经系统改善,与常规治疗组相比,其ΔNIHSS评分具有统计学上的显着差异(p<0.001)。在早期神经系统恶化中没有观察到显着差异(11.10%vs.13.00%,p=1.000),颅内出血(33.33%vs.8.70%,p=0.121),住院死亡率(22.20%vs.26.10%,p=1.000),90天死亡率(55.60%vs.87.00%,p=0.076),或90天mRS评分(p=0.052)。
结论:尽管90天内死亡率很高,再灌注治疗有可能改善Trousseau相关脑梗死患者生存质量.
背景:Trousseau综合征相关性脑梗死,再灌注治疗,静脉溶栓,机械血栓切除术,急性脑梗死.
OBJECTIVE: To evaluate the efficacy and prognostic significance of reperfusion therapy in patients with Trousseau syndrome-related cerebral infarction.
METHODS: Descriptive study. Place and Duration of the Study: Department of Neurology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China, and The Second Affiliated Hospital of Xiamen Medical College, Xiamen, China, between January 2017 and December 2023.
METHODS: Patients with Trousseau-associated cerebral infarction who were treated at two hospitals were included in the study. Clinical outcomes, including early neurological deterioration, intracranial haemorrhage, in-hospital mortality, 90-day modified Rankin scale (mRS) score, 90-day mortality, initial and discharge National Institutes of Health Stroke Scale (NIHSS) score, and ΔNIHSS (difference between the initial and discharge NIHSS score), were compared between the reperfusion-treated group (n = 9) and the conventionally treated group (n = 23).
RESULTS: Patients who received reperfusion therapy demonstrated significant neurological improvement at discharge, with a statistically significant difference in their ΔNIHSS scores compared to those of the conventionally treated group (p <0.001). No significant differences were observed in early neurological deterioration (11.10% vs. 13.00%, p = 1.000), intracranial haemorrhage (33.33% vs. 8.70%, p = 0.121), in-hospital mortality (22.20% vs. 26.10%, p = 1.000), 90-day mortality (55.60% vs. 87.00%, p = 0.076), or 90-day mRS score (p = 0.052) between the two groups.
CONCLUSIONS: Despite the high mortality rate within 90 days, reperfusion therapy has the potential to improve the quality of life of surviving cancer patients with Trousseau-associated cerebral infarction.
BACKGROUND: Trousseau syndrome-related cerebral infarction, Reperfusion therapy, Intravenous thrombolysis, Mechanical thrombectomy, Acute cerebral infarction.